Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03MYO
|
|||
| Former ID |
DIB001166
|
|||
| Drug Name |
MGL-3196
|
|||
| Indication | Familial hypercholesterolemia [ICD-11: 5C80.00; ICD-10: E78.0] | Phase 2 | [1] | |
| Hypercholesterolaemia [ICD-11: 5C80.0] | Phase 1 | [2] | ||
| Hyperlipidaemia [ICD-11: 5C80; ICD-10: E78.5] | Phase 1 | [3] | ||
| Company |
Madrigal pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H12Cl2N6O4
|
|||
| Canonical SMILES |
CC(C)C1=CC(=NNC1=O)OC2=C(C=C(C=C2Cl)N3C(=O)NC(=O)C(=N3)C#N)Cl
|
|||
| InChI |
1S/C17H12Cl2N6O4/c1-7(2)9-5-13(22-23-15(9)26)29-14-10(18)3-8(4-11(14)19)25-17(28)21-16(27)12(6-20)24-25/h3-5,7H,1-2H3,(H,23,26)(H,21,27,28)
|
|||
| InChIKey |
FDBYIYFVSAHJLY-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 920509-32-6
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Thyroid hormone receptor beta (THRB) | Target Info | Agonist | [3] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Thyroid hormone signaling pathway | ||||
| Pathway Interaction Database | RXR and RAR heterodimerization with other nuclear receptor | |||
| Reactome | Nuclear Receptor transcription pathway | |||
| WikiPathways | SIDS Susceptibility Pathways | |||
| Hematopoietic Stem Cell Differentiation | ||||
| Nuclear Receptors | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ClinicalTrials.gov (NCT01367873) Ascending Single-Dose Study to Evaluate VIA-3196 in Healthy Subjects. U.S. National Institutes of Health. | |||
| REF 3 | Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-beta agonist. Atherosclerosis. 2013 Oct;230(2):373-80. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.